Therapy Areas: Oncology
Allogene Therapeutics Prices USD 324m US Initial Public Offering
11 October 2018 - - US-based biotechnology company Allogene Therapeutics, Inc has priced its initial public offering of 18m shares of its common stock at a price to the public of USD 18.00 per share, the company said.

Gross proceeds to Allogene Therapeutics from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be USD 324m. 

The shares are expected to begin trading on the NASDAQ Global Select Market on October 11, 2018 under the symbol "ALLO."

The offering is expected to close on 15 October 2018, subject to customary closing conditions.

In addition, Allogene Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 2,700,000 shares of common stock.

Goldman Sachs and Co. LLC, J.P. Morgan Securities LLC, Cowen and company, LLC and Jefferies LLC are acting as the joint book-running managers for the offering.

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T) therapies for cancer.


Related Headlines